Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis

被引：122

作者：

Kim, Y. H. ^{[1
]}

Yang, T. Y. ^{[2
]}

Park, C-S ^{[3
]}

Ahn, S-H ^{[4
]}

Son, B. K. ^{[4
]}

Kim, J. H. ^{[4
]}

Lim, D. H. ^{[4
]}

Jang, T. Y. ^{[1
]}

机构：

[1] Inha Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Inchon, South Korea

[2] CoA ENT Clin, Inchon, South Korea

[3] Inha Univ, Coll Med, Dept Pharmacol, Inchon, South Korea

[4] Inha Univ, Coll Med, Dept Pediat, Inchon, South Korea

来源：

ALLERGY | 2012年 / 67卷 / 02期

关键词：

allergic rhinitis; allergy; atopy; interleukin-33; AIRWAY INFLAMMATION; NASAL-MUCOSA; HUMAN EOSINOPHILS; IMMUNE-RESPONSES; IN-VITRO; ST2; GENE; T-CELLS; B-CELLS; IL-33; EXPRESSION;

D O I：

10.1111/j.1398-9995.2011.02735.x

中图分类号：

R392 [医学免疫学];

学科分类号：

100108 [医学免疫学];

摘要：

Background: Interleukin (IL)-33 is involved in the Th2 immune response and could play an essential role in nasal allergy. Therefore, we aimed to investigate the therapeutic potential of anti-IL-33 for allergic rhinitis (AR). Methods: Twenty-four BALB/c mice were used. In group A (control group, n = 6), mice were sensitized and challenged with saline. Group B [ovalbumin (OVA) group, n = 6] mice received intraperitoneal and intranasal OVA challenge. In group C (control IgG group, n = 6), mice were injected intraperitoneally with rabbit control IgG before OVA challenge. In group D (anti-IL-33 group, n = 6), anti-IL-33 was injected before challenge. We evaluated the number of nose-scratching events and external morphology; serum total and OVA-specific IgE; number of eosinophils, neutrophils, and lymphocytes in bronchoalveolar lavage (BAL) fluid; histopathologic examination of nasal cavity; and IL-4, IL-5, and IL-13 in BAL fluid. Results: Anti-IL-33 treatment significantly reduced the nose-scratching events and ameliorated skin denudation. Serum total and OVA-specific IgE was significantly decreased in group D. The number of eosinophils in BAL fluid was also significantly decreased. Eosinophilic infiltration in the nasal cavity was significantly decreased in group D. IL-4, IL-5, and IL-13 in BAL fluid were also significantly decreased after treatment. Conclusions: Anti-IL-33 antibody has a therapeutic potential for experimental AR.

引用

页码：183 / 190

页数：8

共 26 条

[1]

[Anonymous], 2008, LAB INVEST, DOI DOI 10.1038/LABINVEST.2008.82

[2]

BRADDING P, 1993, J IMMUNOL, V151, P3853

[3]

A novel IL-1 family cytokine, IL-33, potently activates human eosinophils [J].